Learn from China (Asia)
This article was originally published in PharmAsia News
China's recent quality problems with food and pharmaceutical exports have tarnished its reputation and could become a concern for all of Asia's pharmaceutical industries. For instance, India imports large quantities of raw materials for antibiotics from China, and this has drawn concern from Indian and U.S. authorities. In fact, India exported around $800 million in drugs and pharmaceutical ingredients to the United States in 2006. This trade volume ranks above the $675 million of such products sent to the United States by China. Indian pharmaceutical laws are not evenly enforced or well-funded across all provinces. This one day may result in negative world attention such as the scandals experienced recently by China. (Click here for more
You may also be interested in...
Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.